Twist Bioscience (TWST) Expected to Announce Earnings on Thursday

Twist Bioscience (NASDAQ:TWST) is projected to release its Q4 2026 results before the market opens on Thursday, November 12th. Analysts expect Twist Bioscience to post earnings of ($0.3845) per share and revenue of $123.55 million for the quarter. Parties may review the information on the company’s upcoming Q4 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 12, 2026 at 8:00 AM ET.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.05). The firm had revenue of $118.38 million for the quarter, compared to analysts’ expectations of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%. The company’s quarterly revenue was up 23.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.33 EPS. On average, analysts expect Twist Bioscience to post ($2.12) EPS for the current fiscal year and ($1.56) EPS for the next fiscal year.

Twist Bioscience Stock Performance

Shares of TWST opened at $142.58 on Thursday. The company’s 50 day simple moving average is $152.59 and its 200-day simple moving average is $90.28. The firm has a market cap of $8.94 billion, a PE ratio of -64.22 and a beta of 2.25. Twist Bioscience has a 12-month low of $23.30 and a 12-month high of $219.71. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03.

Insiders Place Their Bets

In related news, CAO Robert F. Werner sold 1,482 shares of the company’s stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $188.88, for a total transaction of $279,920.16. Following the transaction, the chief accounting officer owned 42,917 shares of the company’s stock, valued at $8,106,162.96. This represents a 3.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 10,088 shares of the stock in a transaction dated Friday, October 2nd. The shares were sold at an average price of $188.88, for a total transaction of $1,905,421.44. Following the completion of the transaction, the senior vice president directly owned 106,632 shares of the company’s stock, valued at approximately $20,140,652.16. This trade represents a 8.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 601,920 shares of company stock valued at $93,768,202. Corporate insiders own 3.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on TWST shares. UBS Group initiated coverage on shares of Twist Bioscience in a research note on Wednesday, September 9th. They set a “neutral” rating and a $144.00 price target for the company. Leerink Partners increased their target price on shares of Twist Bioscience from $160.00 to $190.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 29th. TD Cowen increased their target price on shares of Twist Bioscience from $115.00 to $190.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Robert W. Baird raised their price target on Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a report on Tuesday, August 4th. Finally, Piper Sandler increased their price objective on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Seven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $153.00.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.